358 related articles for article (PubMed ID: 17234366)
41. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts.
Fareed A; Casarella J; Amar R; Vayalapalli S; Drexler K
J Psychiatr Pract; 2009 May; 15(3):227-34. PubMed ID: 19461397
[TBL] [Abstract][Full Text] [Related]
42. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
43. Depression in methadone maintenance treatment patients: rate and risk factors.
Peles E; Schreiber S; Naumovsky Y; Adelson M
J Affect Disord; 2007 Apr; 99(1-3):213-20. PubMed ID: 17055063
[TBL] [Abstract][Full Text] [Related]
44. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
[TBL] [Abstract][Full Text] [Related]
45. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.
Elkader AK; Brands B; Dunn E; Selby P; Sproule BA
J Clin Psychopharmacol; 2009 Feb; 29(1):77-81. PubMed ID: 19142113
[TBL] [Abstract][Full Text] [Related]
46. Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations.
Tennant F; Shannon J
J Addict Dis; 1995; 14(1):67-74. PubMed ID: 7632748
[TBL] [Abstract][Full Text] [Related]
47. Quality of life among heroin users on buprenorphine versus methadone maintenance.
Ponizovsky AM; Grinshpoon A
Am J Drug Alcohol Abuse; 2007; 33(5):631-42. PubMed ID: 17891656
[TBL] [Abstract][Full Text] [Related]
48. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
49. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism.
Linnet K; Wiborg O
Clin Pharmacol Ther; 1996 Jul; 60(1):41-7. PubMed ID: 8689810
[TBL] [Abstract][Full Text] [Related]
50. Development and validation of the scale to assess satisfaction with medications for addiction treatment-methadone for heroin addiction (SASMAT-METHER).
de los Cobos JP; Trujols J; Siñol N; Batlle F
Drug Alcohol Depend; 2014 Sep; 142():79-85. PubMed ID: 24975476
[TBL] [Abstract][Full Text] [Related]
51. Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach.
Bleich A; Gelkopf M; Weizman T; Adelson M
Isr J Psychiatry Relat Sci; 2002; 39(2):104-12. PubMed ID: 12227225
[TBL] [Abstract][Full Text] [Related]
52. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
Ngo HT; Tait RJ; Hulse GK
Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
[TBL] [Abstract][Full Text] [Related]
53. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.
Uehlinger C; Crettol S; Chassot P; Brocard M; Koeb L; Brawand-Amey M; Eap CB
J Clin Psychopharmacol; 2007 Jun; 27(3):273-8. PubMed ID: 17502774
[TBL] [Abstract][Full Text] [Related]
54. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
55. CYP2D6 in the brain: genotype effects on resting brain perfusion.
Kirchheiner J; Seeringer A; Godoy AL; Ohmle B; Maier C; Beschoner P; Sim EJ; Viviani R
Mol Psychiatry; 2011 Mar; 16(3):237, 333-41. PubMed ID: 20368706
[TBL] [Abstract][Full Text] [Related]
56. Development and psychometric properties of the Verona Service Satisfaction Scale for methadone-treated opioid-dependent patients (VSSS-MT).
de los Cobos J; Valero S; Haro G; Fidel G; Escuder G; Trujols J; Valderrama JC
Drug Alcohol Depend; 2002 Oct; 68(2):209-14. PubMed ID: 12234650
[TBL] [Abstract][Full Text] [Related]
57. Predictors of retention in methadone programs: a signal detection analysis.
Villafranca SW; McKellar JD; Trafton JA; Humphreys K
Drug Alcohol Depend; 2006 Jul; 83(3):218-24. PubMed ID: 16384657
[TBL] [Abstract][Full Text] [Related]
58. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication.
Pułczyńska A; Łukaszkiewicz J; Wojnar M; Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
Acta Pol Pharm; 2011; 68(1):9-13. PubMed ID: 21485696
[TBL] [Abstract][Full Text] [Related]
59. Doxepin inhibits CYP2D6 activity in vivo.
Szewczuk-Bogusławska M; Kiejna A; Beszłej JA; Orzechowska-Juzwenko K; Milejski P
Pol J Pharmacol; 2004; 56(4):491-4. PubMed ID: 15520506
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
